miR-369-3p Modulation of C/EBP-β to Reduce Inflammatory Cytokines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory diseases, particularly inflammatory bowel diseases, often focus on symptom control rather than addressing the underlying inflammatory response, and there is a need for a pharmaceutical composition that specifically modulates inflammatory mediators like TNFα and IL-6, with miR-369-3p showing potential in regulating these pathways but not fully explored in existing literature.
Innovation Solution
A pharmaceutical composition containing miR-369-3p as the active ingredient, which is upregulated in healthy tissues and downregulated in inflamed areas, modulates the expression of C/EBP-β, reducing the production of TNFα and IL-6 by targeting dendritic cells, thereby providing an anti-inflammatory effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for chronic inflammatory diseases are used, then symptom control is achieved, but the underlying inflammatory response is not addressed
Solution Approach 1:
The patent extracts and isolates the specific miR-369-3p molecule from the complex inflammatory response system. By identifying this single microRNA as a key regulator of TNFα and IL-6 production in dendritic cells, the invention extracts the essential therapeutic target from the complex inflammatory pathway, enabling targeted intervention that addresses the root cause rather than just symptoms.
Solution Approach 2:
The patent introduces miR-369-3p as an intermediary molecule that mediates the regulation between dendritic cells and inflammatory cytokine production. This microRNA acts as a natural intermediary within the immune system that can be therapeutically manipulated to control the inflammatory response, providing a bridge between cellular immunity and cytokine regulation.
2Manufacturing precision
If miR-369-3p is used as active ingredient, then specific modulation of inflammatory mediators is achieved, but the composition complexity increases
Solution Approach 1:
The patent applies local quality by focusing the therapeutic action of miR-369-3p specifically on dendritic cells and their production of TNFα and IL-6. Rather than broadly suppressing all inflammation, the invention concentrates the modulatory effect on specific cell types and cytokines, achieving precise local regulation within the immune system while maintaining overall system balance.
Solution Approach 2:
The patent utilizes parameter changes by modifying the expression levels of miR-369-3p as the key therapeutic parameter. By controlling the concentration and activity of this specific microRNA, the invention achieves precise modulation of inflammatory mediator production through a single controllable parameter, simplifying the pharmaceutical composition while maintaining high specificity.
3Ease of operation
If conventional symptom control treatments are used, then patient quality of life is maintained, but the chronic inflammatory process continues
Solution Approach 1:
The patent applies preliminary action by targeting miR-369-3p to prevent and address the underlying inflammatory process before it progresses to severe symptoms. By intervening at the level of dendritic cell cytokine production rather than waiting for full-blown inflammatory symptoms, the treatment prevents chronic inflammation from establishing, potentially reducing long-term disease duration and severity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces inflammatory cytokine production, offering a novel approach to treating chronic inflammatory diseases by specifically targeting miR-369-3p's role in regulating the inflammatory response in dendritic cells, potentially providing a more targeted therapy for conditions like ulcerative colitis and rheumatoid arthritis.
Implementation Method 1
They play an important regulatory role in inhibiting the translation of specific mRNAs, acting as important regulators of the various processes including cell proliferation, apoptosis, fat metabolism, neuronal patterning, hematopoietic differentiation and immunity
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
The present invention relates to a pharmaceutical composition comprising one or more microRNAs, at least one vehicle and/or diluent and/or excipient pharmaceutically acceptable, characterized by comprising miR-369-3p as active ingredient. This composition is indicated for use in the treatment of chronic inflammatory diseases, in particular for the treatment of inflammatory bowel diseases.